UCB PHARMA

​At UCB, we are consistently delivering on our commitment to improve the lives of people living with severe neurological and immunological conditions.  

And thanks to our focused, innovative and trusted solutions, our business is strong, with total revenue reaching €5.5 billion in 2022.  
 
This success is powered by the approximately 8,700 people – from our headquarters in Belgium and across nearly 40 countries worldwide.  

Our people have lived our purpose each day since 1928, making critical investments in biopharmaceutical research and leading innovations that strive to achieve a meaningful impact on the lives of those we serve. 

UCB’s ambition is to transform the lives of people living with severe diseases, allowing them to live the best life that they can – as free as possible from the challenges and uncertainty of disease.  

That commitment comes to life in our research and development activities across neurology, immunology and other areas where our expertise, innovation and ambition align with unmet needs.  

UCB is continuously working to advance science and embrace new knowledge, bringing passion and leadership to solving the challenges that matter to people living with severe diseases.  

We are leveraging scientific advances and new technologies in areas including genetics, biomarkers and human biology.  

Continually inspired by those we serve to bring differentiated solutions with unique outcomes that deliver tangible, positive impacts.